Bright Minds Biosciences Inc. DRUG
51.80
(1.71)
(3.20%)
as of 25 Sep
- Market cap
- $527.8M
- P/E
- 0.0×
Follow DRUG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
121.98 | 81.48 | 57.37 | 36.10 |
+8 more quarters Free account |
Net Debt/EBITDA |
26.97 | 20.24 | 12.93 | 14.54 | |
Debt/Assets |
0.00% | 0.00% | 0.02% | 0.05% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
3.42 | 0.89 | 0.77 | 0.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.60) | (0.71) | (0.54) | (0.12) | |
Cash per Share |
22.62 | 23.54 | 8.23 | 8.62 | |
Shareholders Equity per Share |
22.62 | 23.45 | 8.25 | 8.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
22.62 | 23.45 | 8.25 | 8.53 | |
Free Cash Flow |
(5.92) | (6.81) | (4.17) | (0.85) | |
Working Capital |
222.28 | 224.84 | 63.99 | 58.60 | |
Net Current Asset Value |
222.28 | 224.84 | 63.97 | 58.57 | |
| Other line items | |||||
Quick Ratio |
121.44 | 81.10 | 56.58 | 35.68 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.60) | (0.71) | (0.54) | (0.12) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.50 | 0.50 | 0.20 | 0.17 | |
Average Payables |
1.09 | 1.56 | 0.67 | 0.97 | |
Average Assets |
131.06 | 133.50 | 53.45 | 32.42 | |
Average Common Equity |
129.90 | 131.85 | 52.67 | 31.36 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates